VP 16.213 in the Treatment of Acute and Chronic Leukaemias

  • R. Willemze


Acute leukaemia is a heterogenous group of diseases with regard to cytological criteria but also with regard to the clinical course and treatment.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bernasconi, C., et al: Etoposide (VP 16.213) in the treatment of acute monocytic and myelomonocytic leukaemias. Chemioterapia 1, 181–186 (1982).Google Scholar
  2. 2.
    Bern, M. M., et al: Age stratified chemotherapy with up front VP 16.213, for acute non-lymphoblastic leukaemia. Blood 60 (Suppl.), 151a (1982).Google Scholar
  3. 3.
    Cavalli, F: VP 16.213: a critical review of its activity. Chemioterapia 1, 102–108 (1982).Google Scholar
  4. 4.
    European Organization for Research on the Treatment of Cancer, Clinical Screening Group: Epipodophyllotoxin VP 16.213 in Treatment of Acute Leukaemia, Haematosarcomas, and Solid Tumours. Brit. Med. J. 3, 199–202 (1973).CrossRefGoogle Scholar
  5. 5.
    Jacobs, P., et al: VP 16.213 in acute non-lymphoblastic leukaemia. Brit. Med. J. 1, 396 (1975).PubMedCrossRefGoogle Scholar
  6. 6.
    Mathe, G., et al: Two epipodophyllotoxin derivatives, VM26 and VP 16.213 in the treatment of leukemias, hematosarcomas, and lymphomas. Cancer 34, 985–992 (1974).PubMedCrossRefGoogle Scholar
  7. 7.
    McKenna, R. W., et al: Acute monoblastic leukemia: diagnosis and treatment of ten cases. Blood 46, 481–494 (1975).PubMedGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1984

Authors and Affiliations

  • R. Willemze
    • 1
  1. 1.Leiden Universital Medical CentreLeidenThe Netherlands

Personalised recommendations